GSK secured broader FDA clearance for its respiratory syncytial virus (RSV) vaccine Arexvy, expanding approved indications and potentially boosting uptake after an initially sluggish launch. The agency action follows additional data submissions and signals regulatory receptivity to new preventive options for older adults. The expanded label could accelerate vaccination campaigns in target populations and generate renewed commercial momentum for GSK’s vaccine franchise. Market access and uptake will hinge on payer coverage, public health recommendations, and comparative positioning versus other RSV products.